Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             41 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Acknowledgement to Reviewers 2019
139 C p. 226-229
 artikel
2 Aims and Scope/Editorial Board
139 C p. iii
 artikel
3 Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series Ribeiro, Maurício Fernando Silva Almeida
139 C p. 9-12
 artikel
4 Attending community-based lung cancer screening influences smoking behaviour in deprived populations Balata, Haval
139 C p. 41-46
 artikel
5 Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation Wiesweg, Marcel
139 C p. 165-168
 artikel
6 Contents
139 C p. v-vii
 artikel
7 Corrigendum to “External validation of prognostic indices for overall survival of malignant pleural mesothelioma” [Lung Cancer 113 (November) (2017) 88–92] Kataoka, Yuki
139 C p. 225
 artikel
8 Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity Zeltsman, Masha
139 C p. 68-72
 artikel
9 Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision Sousa, AC.
139 C p. 35-40
 artikel
10 Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma Stockhammer, Paul
139 C p. 124-132
 artikel
11 Development of a predictive radiomics model for lymph node metastases in pre-surgical CT-based stage IA non-small cell lung cancer Cong, Mengdi
139 C p. 73-79
 artikel
12 Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model Moldaver, Daniel
139 C p. 185-194
 artikel
13 Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study Zhang, Jia-Tao
139 C p. 118-123
 artikel
14 Educational level, management and outcomes in small-cell lung cancer (SCLC): A population-based cohort study Tendler, Salomon
139 C p. 111-117
 artikel
15 Erratum to “Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme” [Lung Cancer 134 (August) (2019) 66–71] Ghimire, Bhagabati
139 C p. 224
 artikel
16 Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer Nakagawa, Kazuhiko
139 C p. 195-199
 artikel
17 Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy Thompson, Jeffrey C.
139 C p. 1-8
 artikel
18 Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review Zhang, Dongxiao
139 C p. 18-21
 artikel
19 Impact of coexisting gene mutations in EGFR-mutated non–small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs Takeda, Masayuki
139 C p. 28-34
 artikel
20 Joint use of the radiomics method and frozen sections should be considered in the prediction of the final classification of peripheral lung adenocarcinoma manifesting as ground-glass nodules Wang, Bin
139 C p. 103-110
 artikel
21 Long-term cancer risk associated with lung nodules observed on low-dose screening CT scans Pinsky, Paul
139 C p. 179-184
 artikel
22 Lung cancer surgical treatment after solid organ transplantation: A single center 30-year experience Drevet, Gabrielle
139 C p. 55-59
 artikel
23 Molecular profiling of thymoma with myasthenia gravis: Risk factors of developing myasthenia gravis in thymoma patients Lee, Ming-Ching
139 C p. 157-164
 artikel
24 Oligometastatic non-small cell lung cancer (NSCLC): Does number of metastasis matter? Giaj-Levra, Niccolò
139 C p. 216-218
 artikel
25 Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways Caraceni, Augusto
139 C p. 13-17
 artikel
26 Phase II study of S-1 in patients with previously-treated invasive thymoma and thymic carcinoma: North Japan lung cancer study group trial 1203 Tsukita, Yoko
139 C p. 89-93
 artikel
27 Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer Gerber, David E.
139 C p. 60-67
 artikel
28 PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors Li, Tao
139 C p. 146-150
 artikel
29 Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer Ou, Sai-Hong Ignatius
139 C p. 22-27
 artikel
30 Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors Matsumoto, Yoshiya
139 C p. 80-88
 artikel
31 Psuedoprogression mimicking hyperprogressive disease after pembrolizumab treatment in a patient with lung cancer Hashimoto, Kosuke
139 C p. 221-223
 artikel
32 Publisher’s Note ‘Phase 2 Study of the Focal Adhesion Kinase Inhibitor Defactinib (VS-6063) in Previously Treated Advanced KRAS Mutant Non-small Cell Lung Cancer’
139 C p. 169
 artikel
33 Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018 Reale, Maria Lucia
139 C p. 47-54
 artikel
34 Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation Zhou, Fei
139 C p. 219-220
 artikel
35 Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells Miyake, Noriko
139 C p. 170-178
 artikel
36 The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer Ichihara, Eiki
139 C p. 140-145
 artikel
37 The role of surgery for atypical bronchopulmonary carcinoid tumor: Development and validation of a model based on Surveillance, Epidemiology, and End Results (SEER) database Chen, Xiaowei
139 C p. 94-102
 artikel
38 The utility of endosonography for mediastinal staging of non-small cell lung cancer in patients with radiological N0 disease Shin, Sun Hye
139 C p. 151-156
 artikel
39 Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates Blom, Erik F.
139 C p. 200-206
 artikel
40 Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC Yang, Shuo
139 C p. 133-139
 artikel
41 Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis Tan, Aaron C.
139 C p. 207-215
 artikel
                             41 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland